诺和诺德因Wegovy口服药和Ozempic需求持续上调展望 (NVO:NYSE)
· seekingalpha.com
诺和诺德上调展望，Wegovy和Ozempic推动GLP-1销售增长。
Novo (NVO) raised its outlook for the year once again, driven by continued demand for its Wegovy weight-loss pill, and its older shot Ozempic.
The Danish drugm...